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ABSTRACT
The c-Myc transcription factor regulates a complex transcriptional program that
leads to cellular transformation by targeting a large number of protein-encoding genes
and non-coding RNAs. In this study, we show that a microRNA, miR-200c, is a novel
c-Myc target that promotes cellular transformation and metastasis in nasopharyngeal
carcinoma. MiR-200c achieves this oncogenic effect, at least in part, by targeting
and inhibiting the tumor suppressor gene PTEN (phosphatase and tensin homolog),
which is a key inhibitor of the AKT kinase signaling that promotes tumorigenesis in
nasopharyngeal carcinoma. Our study thus identifies cMyc-miR-200c-PTEN-AKT as a
functional module that promotes cellular transformation in nasopharyngeal carcinoma.

MiR-200c is a member of the miR-200 family
which consists of miR-200a, miR-200b, and miR-200c,
miR-141 and miR-429. In humans, miR-200a, miR-200b
and miR-429 are located on chromosome 1 whereas
miR-200c and miR-141 are located on chromosome
12 [12]. Members of the miR-200 family are highly
enriched in epithelial tissues [13]. A recent study
showed that miR-200c inhibited invasion and
migration in human colon cancer cells (SW480/620) by
targeting ZEB1 suggesting that it could be a metastasis
suppressing miRNA which is opposite to our findings
[14]. However, many studies have demonstrated that
miR-200c is positively associated with malignancy of
human cancers. Croce and colleagues found that the
miR-200 family (miR-200a, miR-200b, miR-200c and
miR-141) was upregulated in human ovarian cancers,
especially in serous and Endometrioid histotypes [15].

INTRODUCTION
The c-Myc oncogene encodes an evolutionarily
conserved basic helix-loop-helix leucine zipper
transcription factor that is commonly dysregulated
in cancer, resulting in pleiotropic effects on cancer
cell growth, proliferation, survival, angiogenesis, and
metastasis [1, 2]. Recent studies have demonstrated
that c-Myc exerts its oncogenic role by its ability
to dramatically reprogramme microRNA (miRNA)
expression that simultaneously modulate complex
genetic networks including various oncogenes and tumor
suppressor genes by inhibiting translation of their mRNAs
[3–7]. Although many c-Myc targeted miRNAs have been
implicated in cancer, newer miRNAs that have key roles in
mediating tumorigenes is need to be identified and studied
[8–11].
www.impactjournals.com/oncotarget
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RESULTS

A subsequent study confirmed this finding in serous
ovarian cancers [16]. Moreover, overexpression of
miR-200c in non-metastatic 4TO7 cells resulted
in epithelial-mesenchymal transition (EMT) and
colonisation of the liver and lung [17, 18].
In this study, we demonstrated that miR-200c, is
a c-Myc regulated miRNA that influences oncogenic
transformation by inhibiting the tumor suppressor gene
PTEN resulting in subsequent activation of serine/
threonine kinase, AKT.

c-Myc inhibition decreases miRNA-200c levels
To study the role of c-Myc in nasopharyngeal
carcinoma (NPC), we used a stable NPC 5-8F cell line in
which endogenous c-Myc was downregulated by siRNA
[19]. We used a miRNA microarray to analyse the miRNA
profile changes between the 5-8F/Si-c-Mycand the 5-8F/
Si-control cell lines (Figure 1A). This miRNA microarray

Figure 1: MicroRNA profile changes due to c-Myc inhibition in 5-8F NPC cells. A. The miRNA microarray results for 5-8F/

Si-c-Myc and 5-8F/Si-control cells. B. The fluorescence value for miR-200c from the miRNA microarray results. C. Northern blot analysis
showing relative expression levels of miR-200c normalized to U6 (control) in the samples used for the microarray. D. Real-time PCR
analysis showing relative expression levels of miR-200c normalized to U6 (control) in the samples used for the microarray chip.
www.impactjournals.com/oncotarget
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measures the expression of 434 human, 196 rat and 261
mouse miRNAs (Figure 1A). Our study found that upon
c-Myc downregulation, twelve human miRNAs were
upregulated and seven miRNAs were downregulated
(with a fold change >3) in the 5-8F/Si-c-Myc cell line. The
most dramatically downregulated miRNA was miR-200c
that showed a 10 fold change. Since we had previously
demonstrated the role of miR-216b in the nasopharyngeal
carcinoma-related gene network [24], we wanted to explore
the role of miR-200c in NPC. To exclude false-positives
from the miRNA microarray analysis, we confirmed the
downregulation of miR-200c in 5-8F/Si-c-Myc cells by
Northern blot and RT-PCR analyses (Figures 1B-1D).

Since c-Myc functions as an oncogene in NPC, we
postulated that the role of miR-200c in 5-8F cells was to
control its downstream targets. Therefore, we tested miR200c expression in 10 NPC and 10 normal nasopharyngeal
epithelium specimens by RT-PCR. The tissue samples
were obtained by laser-capture microdissection and the
lymphocytes and interstitial cells were removed prior to
RNA extraction (Figure 2A). The results showed that the
average expression levels of miR-200c and c-Myc were
significantly higher and the average expression levels of
PTEN were significantly lower in the NPC specimens
than in the normal nasopharyngeal epithelium tissues
(P<0.05; Figure 2B-2D). Moreover, the expression level

Figure 2: MiR-200c is upregulated in NPC specimens. A. Top panel shows representative photographs (×100) of normal

nasopharyngeal epithelium microdissection and the bottom panel shows NPC epithelium. The samples were stained with methyl
green. B. Real-time PCR data showing relative expression levels of miR-200c in10 normal tissues and 10 NPC tissues. Data were
normalized to U6 mRNA (control) and statistically analysed by unpaired Student’s t-test (P =0.0021). C. Real-time PCR analysis showing
relative expression levels of c-Mycin10 normal tissues and 10 NPC tissues. Data were normalised to that of GAPDH (control) and analysed
by unpaired Student’s t-test (P =0.0064). D. Real-time PCR analysis showing the relative expression levels of PTEN with 10 normal tissues
and 10 NPC tissues. Data were normalised to that of GAPDH (control) and statistically analysed by unpaired Student’s test (P=0.0075).
E. The relationship between c-Myc and miR-200c. F. The relationship between miR-200c and PTEN.
www.impactjournals.com/oncotarget
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of miR-200c was found to be directly correlated with
the expression level of c-Myc (P < 0.05; Figure 2E), but
inversely correlated with PTEN (P < 0.05; Figure 2F).

between days 3 and 6 post treatment, whereas the miR200c mimic significantly increased the viability of the
5-8F cells suggesting that the miR-200c levels regulated
NPC cell viability.
Since the 5-8F cell line is highly metastatic,we studied
the effect of miR-200c inhibitor on the cell cycle and cell
invasiveness. Cell cycle analysis showed that inhibition of
miR-200c by the 200cI arrested the cells in G0-G1 phase.
We found increased cells in the G0–G1 phase (42% to 66%),
reduced number of cells in the S phase (30% to 17%) and
no effect on the G2–M phase of the cell cycle (Figure 3C).
In addition, we observed enhanced apoptosis of 5-8F cells
(Figure 3D). These data therefore suggested that miR200c is
required for cell cycle progression and survival.
To study the effect of miR-200c on the migration
and mobility of the 5-8F cells, we performed an in vitro

MiR-200c increases cell cycle and promotes
cellular migration and invasiveness
To study the cellular function of miR-200c in NPC,
we transfected the miR-200c mimic (200cM) and the
miR-200c inhibitor (200cI) with their appropriate negative
controls into 5-8F NPC cells. As expected, we found that
the mimic increased the levels of miR-200c whereas the
inhibitor decreased its levels (Figure 3A). To study the
effect of miR-200c on growth of 5-8F cells, we performed
the MTT assay. We found that the miR-200c inhibitor
significantly decreased the viability of the 5-8F cells

Figure 3: Inhibition of miR-200c expression reduces growth, cell cycle, invasiveness of 5-8F NPC cells and promotes cell
apoptosis. A. The 5-8F NPC cells were transfected with 200cM (mimic), 200cI (inhibitor) or their corresponding control miRNAs (NC

or INC). Cells were harvested at 24 h post-transfection and the endogenous miR-200c level was measured using RT-PCR and normalized
to U6 mRNA. B. The data from the MTT assay that was performed each day for 6 days after transfection with the miR-200c mimic and
the inhibitor. Each value represents the Mean ± SEM for at least three observations. *P<0.05 compared with controls. C. Flow cytometric
analyses of the cell cycle of each treatment group. D. Flow cytometric analysis showing percent apoptosis in each treatment group. E. The
number of migrated cells in each group in the in vitro transwell invasion assay is compared to the appropriate controls. Data are Mean ±
SEM; n=3; *P=0.0015. F. The data from the wound-healing assay are shown. The upper panel shows the miR-200c INC or inhibitor group
at 0h. The bottom panel shows the miR-200c INC or inhibitor group at 24h. The changes at the wound edges are illustrated with broken
lines. Data are Mean ± SEM; n=3; *P=0.008.
www.impactjournals.com/oncotarget
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cell invasion assay based on the Boyden chamber assay.
We observed that when treated with the miR200c
inhibitor, 200cI, the number of 5-8F cells migrating
through the matrigel decreased significantly in comparison
to the control group (P<0.05; Figure 3E). Also, when we
performed the in vitro scratch wound healing assay to
study the effect of miR-200c on cell migration, we found
that the 5-8F NPC cells migrated significantly slower in
the miR-200c inhibitor group (P<0.05; Figure 3F). These
results therefore suggested that miR-200c regulated the
cellular migration and invasion properties of the NPC
cells.
We then performed tumor xenograft and pulmonary
metastasis studies with 5-8F NPC cells in BALB/c nude
mice to investigate the role of miR-200c in vivo. Towards
this, the 5-8F cells were collected after transfection with
miR-200c mimic (200cM), miR-200c inhibitor (200cI)

and negative control (NC)for 24h. For tumor xenograft
studies, 200cM/5-8F, 200cI/5-8F and NC/5-8F were
injected subcutaneously into the axillary fossae of the
male BALB/c nude mice. When the tumors were analyzed
5 weeks post xenografting, the tumor volume from
200cI/5-8F cells was smaller than those from the NC/58F cells (Figure 4A). On the other hand, we found that
the tumor volume from 200cM/5-8F cells was larger than
those from NC/5-8F cells (Figure 4B). For pulmonary
metastasis assays, 200cM/5-8F, 200cI/5-8F and NC/58F were injected into nude mice through the lateral tail
vein. After 5 weeks, we found that the number of mice
with lung metastases were lower in the group injected
with 200cI/5-8F cells compared with the group injected
with the NC/5-8F cells, whereas, the number of mice with
lung metastases were higher in the group injected with
200cM/5-8F cells when compared to the group injected

Figure 4: MiRNA-200c accelerates tumour growth and increases the distal pulmonary metastases in vivo. A. Photographs

of mice injected with 200cM/5-8F, 200cI/5-8F and NC/5-8F. B. Tumour weight averages between 200c M/5-8F, 200c I/5-8F and NC/5-8F
mice groups at the endpoint of the experiment (day 35). Data are presented as Mean ± S.D. (n=3). NC/5-8Fvs 200c I/5-8F (P=0.011), NC/58F vs 200c M/5-8F (P=0.005). C. HE staining of lung tissue isolated from nude mice that had been injected with 200cM/5-8F, 200cI/5-8F
or NC/5-8F via lateral tail veins (×200 magnification). The metastasis nodules are indicated by arrows. D. The graph shows the average of
metastatic nodules in the lung of mice that received lateral tail injections of each cell line. Each group had three mice. Fisher’s exact test:
NC/5-8F vs 200c I/5-8F (P = 0.039), NC/5-8F vs 200c M/5-8F (P = 0.0135).
www.impactjournals.com/oncotarget
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with the NC/5-8F cells (Figures 4C-4D). Together, these
data suggest that miR200c accelerates the growth of 5-8F
engrafted tumors and increases the distal pulmonary
metastases in vivo.

significantly decreased luciferase activities (P<0.05) in the
200cM transfected cells, whereas the PTEN Mut showed
diminished regulation of miR-200c. These results showed
that miR-200c inhibited PTEN by directly interacting with
3′UTR of PTEN (Figure 5B).
PTEN is a vital tumor suppressor gene that functions
by inhibiting the PI3K pathway and that regulates multiple
biological processes like apoptosis, metabolism, cell
proliferation and cell growth [25, 26]. Since miRNAs
down regulate their targets by affecting mRNA translation
or mRNA stability, we wanted to detect whether
transfection with 200cI or 200cM affected the PTEN and
p-AKT protein levels. Our analyses revealed that PTEN
was upregulated and p-AKT was downregulated by the
miR200c inhibitor, 200cI (Figure 6C), whereas PTEN
was downregulated and p-AKT was upregulated by the
miR200c mimic, 200cM (Figure 5D). The p-AKT protein
level in 200cM treated cells was comparable to cells
treated with the AKT inhibitor LY294002(40μmol/L)

MiR-200c suppresses PTEN expression by
targeting its 3′UTR
Since miR-200c promoted tumorigenesis in NPC,
we wanted to identify the tumor suppressor genes that
were inhibited by miR-200c. We found PTEN as one of the
miR-200c-targeted genes in the TSGD (Tumor Suppressor
Gene Database). To understand the interaction between
PTEN and miR-200c, we cloned the 3′UTR of PTEN into
a vector downstream of a firefly luciferase reporter gene
with (PTEN WT) or without (PTEN Mut) the predicted
miR-200c binding site (Figure 5A). Further, we transfected
the HEK-293 cells with either of the constructs along with
200cM or NC. We found that the 3′UTRs of PTEN WT

Figure 5: MiR-200c regulates PTEN-AKT signalling pathway in 5-8F NPC cells. A. Schematic representation of the three
reporter constructs named blank, 200c /PTEN WT and 200c/PTEN Mut. ‘Mut’ indicates the mutant construct in which the predicted binding
site of miR-200c was deleted. B. The firefly luciferase vector was co-transfected with the indicated material (no treatment, 10 pmol NC,
10 pmol 200cM) into the HEK293 cells. Luciferase activities were measured after 48 h, and β-galactosidase was used to normalise for
differences in transfection efficiency. Data was confirmed in duplicate experiments. The data are presented as the Mean ± SEM of separate
transfections (n=6); *P = 0.021 compared with no treatment group. C. PTEN protein expression levels were increased and p-AKT protein
levels were decreased upon transfection with 200cI compared to control group in 5-8F cells. D. PTEN protein expression levels were
decreased and p-AKT protein levels were increased upon transfection with 200cM compared with the control group in 5-8F cells. E. The
p-AKT protein level upon transfection with 200cM was similar to that obtained upon treating the cells with the AKT inhibitor (LY294002).
www.impactjournals.com/oncotarget
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(Figure 5E). These results demonstrated that miR-200c
upregulated the AKT signaling pathway by inhibiting
PTEN.

phosphorylation of the AKT target MDM2 was also
inhibited by the knockdown of c-Myc (Figure 6F). These
data showed that c-Myc modulates the AKT signaling
pathway via miR200c regulation of PTEN.

c-Myc activates the AKT pathway by repressing
PTEN

DISCUSSION

Since we identified PTEN as the target gene of
miR-200c and since miR-200c is regulated by c-Myc,
we wanted to study if c-Myc could affect the PTEN
and p-AKT expression levels similar to miR-200c. We
observed that the PTEN mRNA level was upregulated
upon knockdown of c-Myc upon analysis by RT
PCR (Figure 6A). Conversely, the PTEN mRNA was
downregulated upon overexpression of c-Myc (Figure
6B). The Western blot data were consistent with the RTPCR results (Figure 6C–6D). Co-expression of 200cI
with c-Myc abolished the increase in PTEN expression
induced by c-Myc alone (Figure 6E). Furthermore, the

The critical role for c-Myc activity in cancer
development and progression is now well established
[2]. It is clear that a variety of non-coding miRNAs are
regulated by c-Myc and in turn target a number of key
cellular regulatory genes [5, 25, 26]. Results of this study
revealed a crucial role of miR-200c as a novel target of
c-Myc in c-Myc mediated cellular transformation. The
oncogenic function of miR-200c is attributable at least
in part to the inhibition of PTEN, a tumour suppressor
candidate, through targeting the PTEN 3′UTR and
subsequently activating the AKT signalling pathway
(Figure 7).

Figure 6: c-Myc promotes AKT signaling pathway activation by inhibiting PTEN expression. A. RT-PCR data showing

increased PTEN mRNA levels upon knockdown of c-Myc. B. RT-PCR data showing decreased PTEN mRNA levels upon c-Myc
overexpression. C. Western blot data showing increased PTEN protein levels upon c-Myc knockdown. The fold-changes in the PTEN
protein levels were calculated relative to the control. Data is presented as the Mean ± SD (N=3, *p<0.05). D. Western blot data showing
decreased PTEN protein level upon c-Myc overexpression. The fold-changes in the PTEN protein levels were calculated relative to the
control. Data is presented as the Mean ± SD (N=3, *p<0.05). E. The PTEN protein expression remained relatively similar upon coexpression of 200cI with c-MYC. The fold-changes in the PTEN protein levels were calculated relative to the control. Data is presented
as the Mean ± SD (N=3, *p<0.05). F. p-MDM2 levels were lower due to knockdown c-Myc in the 5-8F cells. The fold-changes in the
p-MDM2 protein level were calculated relative to the control. Data is presented as the Mean ± SD (N=3, *p<0.05).
www.impactjournals.com/oncotarget
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The role of miR-200c in NPC has not been well
studied although it has been found to play a role in many
cancers [27–30]. We found that miR-200c was upregulated
in NPC tissue samples in comparison with NPE samples.
Also, since the siRNA downregulation of c-Myc decreased
miR-200c expression we postulated that miR-200c
expression is induced by c-Myc during different stages of
tumorigenesis. Further, we found that inhibition of miR200c reduced cell viability, cell cycle arrest in the G0–
G1 phase and decreased cell migration and invasiveness.
These results suggest that miR-200c is a c-Myc target that
plays a significant role in NPC tumour genesis. In addition
to our findings, miR-200c has been shown to be regulated
by the oncogenic KRAS and PPARα [31].

To understand the role of miR-200c in initiating
the EMT program, we screened for potential targets and
found that the tumor suppressor gene, PTEN, was a direct
target of miR-200c. PTEN is one of the most common
tumor suppressor genes found altered either by mutation
or deletion in human cancers including glioblastoma,
endometrial cancer, and prostate cancer [32, 33].
PTEN is a protein tyrosine phosphatase that negatively
regulates intracellular levels of phosphatidylinositol-3,
4, 5-trisphosphate in cells by dephosphorylating it and
hence negatively regulates the AKT/PKB signalling
pathway [34]. Phosphorylation of AKT is necessary for
the activation of a cascade of multiple protein targets
that are involved in cell growth, proliferation and

Figure 7: Conceptual relationships between miR-200c and nasopharyngeal carcinoma. miR-200c can be activated by

c-myc. Once activated, miR-200c can promote cell migration and invasion through targeting the PTEN 3′UTR and subsequently activating
the AKT signaling pathway.
www.impactjournals.com/oncotarget
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invasion, and hence promote tumorigenesis. Our study
demonstrates that miR-200c upregulation can result
in higher AKT phosphorylation through its inhibition
of PTEN expression. Apart from our finding, recently
the miR-18 cluster has been reported to PTEN [35].
Since PTEN negatively regulates AKT activity, our data
suggests a synergistic mechanism involving miR200c in
creating the metastatic state [36]. The novel mechanism
we propose is that c-Myc activation induces miR-200c that
negatively regulates the expression of tumor suppressor
genes like PTEN resulting in accelerated cellular
growth, invasiveness, and metastasis of NPC. Although
downregulation of PTEN and subsequent activation of
AKT signalling is necessary for miR-200c to facilitate
metastasis, there may be exist other downstream targets of
miR-200c required for metastasis progression that need to
be identified and investigated by future studies.
In summary, we have identified miR-200c as a prometastatic miRNA and a negative regulator of the key
metastasis suppressor, PTEN. Our results revealed that the
miR-200c expression was upregulated by c-Myc in NPC
cells, and the upregulation of miR-200c in turn suppressed
the expression of PTEN, leading to the activation of
AKT signalling pathway, which ultimately promotes
carcinoma cell motility and invasiveness. Although PTEN
downregulation and AKT signalling activation appear to
be necessary for miR-200c to facilitate metastasis, it is
possible that additional miR-200c targets are involved
in the miR-200c promoted metastatic progression.
In this regard, further investigation on the functional
characterization of miR-200c in tumour cells is warranted.

was performed at the Xiangya Hospital of Central South
University (Changsha, China). The tissue samples were
snap frozen in liquid nitrogen and stored at -80°C until
being subjected to laser capture micro-dissection (LCM).
The samples were fully encoded and examined according
to the protocol approved by the Institutional Review Board
of Human Subjects Research Ethics Committee. All the
individuals participating in this study were provided with
informed consent.
8µm-thick frozen sections of fresh NPC and NPE
were prepared using a Leica CM 1900 cryostat (Lecia,
Germany) at -25°C and LCM was performed as previously
described [20].

The miRNA microarray analysis
To identify differences in miRNA profile between
the 5-8F/Si-control and the 5-8F/Si-c-Myc cell lines,
the miRNA microarray analysis was performed using
a miRNA microarray obtained from from Capital Bio
Corporation (Beijing, China) and composed of 434
human (containing 122 predicted miRNA sequences
from a published reference), 196 rat and 261 mouse
miRNAs that were registered in the Sanger miRBase
miRNA database (http://www.mirbase.org/; miRBase
Release 8.2). The miRNA microarray used was a singlechannel fluorescence chip with all oligonucleotide
probes being labelled with Cy3 fluorescent dyes (green
colour). The miRNAs were enriched from total RNAextracted cells (5-8F/Si-c-Myc and 5-8F/Si-control)
using a mirVana miRNA Isolation Kit (Ambion,
Foster City, CA) and labelled using a mirVana Array
Labelling Kit. Labelled miRNAs were then hybridized
to miRNA microarrays that had 509 probes in triplicate
to determine differential expression between the cell
lines. This procedure was repeated twice. Fluorescence
scanning was performed using a double-channel laser
scanner (LuxScan 10K/A; CapitalBio). Figure signals
were transformed to digital signals using image
analysis software (LuxScan3.0; CapitalBio). Raw data
were normalized and analyzed using the Significance
Analysis of Microarrays software (SAM, version 2.1;
Stanford University, CA).

MATERIALS AND METHODS
Cell culture and stable transfection
The Cancer Centre of Sun Yet-Sen University
(Guangzhou, China) kindly provided the NPC cell
line 5-8F for the present study. We generated the 5-8F/
Si-c-Myc cells, by siRNA knockdown of c-Myc and
the negative control (NC) cells (5-8F/Si-control) with
a negative mock siRNA vector using the strategy as
previously reported [19]. All the 5-8F cell lines were
cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum, and maintained in a humidified
atmosphere of 5% CO2 in air at 37°C.

siRNAs transient transfection
MiR-200c mimics (200c M) and miR-200c
inhibitors (200c I) in the form of a short duplex siRNA
duplex were synthesized and purified by Shanghai GenePharma Co. (Shanghai, China). siRNA duplexes with nonspecific sequences were used as the negative control (NC)
and as the inhibitor negative control (INC), respectively.
The four different siRNAs (200cM, 200cI, NC and INC)
were transfected into separate group of 5-8Fcells using
Lipofectamine 2000 (Invitrogen) in accordance with the
manufacturer’s protocol.

Patient samples and LCM
For the miRNA expression study, 10 normal
nasopharyngeal epithelium (NPE) samples and 10
nasopharyngeal carcinoma (NPC) biopsies were obtained
from Xiangya Hospital of Central South University
(Changsha, China). Normal nasopharyngeal epithelium
samples were obtained from biopsy-negative cases. The
clinical and histopathological analysis of the NPC samples
www.impactjournals.com/oncotarget
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RNA isolation and quantitative RT-PCR analysis

The oligonucleotides were digested with HindIII and SpeI
and ligated into pmiR-Report luciferase vector (Ambion,
Austin, TX). Three 3′UTR luciferase reporters were
constructed and named blank, PTEN WT, and PTENMut
(Figure 3B).
Further, the 5-8F cells were seeded in 24-well plates
24 h prior to transfection. The following day, 200ng of
reporter plasmid and 10 pmol of miRNA mimic or mimicNC were co-transfected into cells using Lipofectamine
2000. Luciferase activity was measured in cell lysates 24
h after transfection using a Luciferase Assay kit (Promega,
Madison, WI). β-Galactosidase activity was measured
in cell lysates using the β-galactosidase Enzyme Assay
System (Promega). The results were normalized against
β-galactosidase activity.

Total RNA was isolated using TRIZOL reagent
(Invitrogen, USA) according to the manufacturer’s
instructions. RNA was extracted with the RNeasy
kit (Qiagen, Valencia, CA) and treated with DNase I
according to the manufacturer’s instructions (Qiagen,
Valencia, CA). The integrity and quality of RNA was
confirmed by agarose gel electrophoresis and absorbance
at 260 nm. Total RNA was then reverse transcribed to
cDNA using the SuperScript™ First-Strand Synthesis
System with random hexamer primers ( Promega, USA ).
Real time RT-PCR was performed to detect cellular
miRNAs as previously described [21]. The primers for RTPCR to detect miRNA were designed based on the miRNA
sequences provided by the Sanger Center miRNA Registry
and were synthesized and purified by the Shanghai GenePharma Co. (Shanghai, China). Real-time PCR was
performed on the BIO-RAD IQTM5 Multicolor Real-time
PCR Detection System (Bio-Rad). U6 RNA was used as
an endogenous control for miRNA detection. All reactions
were run in triplicate.

3-(4,5-Dimethylthiazole-2-yl)-2,5-biphenyl
tetrazolium bromide assay
After the transient transfection with miRNA mimics
or inhibitors, the cells (4×103) were seeded into 96well culture plates. Cell viability was determined daily
for 6 days using the (3-(4, 5-Dimethylthiazole-2-yl) -2,
5-biphenyl tetrazolium bromide; Sigma-Aldrich) assays
were performed daily for 6 days. In brief, 0.025 ml of
MTT solution (5 mg/ml) was added to each well, and
the cells were incubated for 4 h. After centrifugation, the
supernatant was carefully removed from each well. The
coloredformazan crystals produced from the MTT were
dissolved in 0.15 ml of dimethyl sulfoxide and mixed for
10 min. The optical density (OD) value was measured
at 570 nm with an enzyme-linked immunosorbent assay
reader.

Northernblot analysis
Northern blot analysis was performed to detect
cellular miRNAs [22]. The blot was reprobed for U6 to
control for equal loading and quantitation performed with
a Storm 860 phospho imager (Molecular Dynamics) and
Image Quant software.

Western blot analysis
Western blotting was performed as described
previously [23]. Anti-β-actin was purchased from SigmaAldrich (St Louis, MO. 1:1000 dilution). The anti-PTEN,
anti-MDM2, and anti-phospho-MDM2 were from Santa
Cruz Biotechnology (Santa Cruz, CA. 1:400 dilution). The
anti-c-Myc was from Upstate Biotechnology (Chicago, IL.
1:1000 dilution). The anti-AKT and anti-phospho-AKT
were from Cell Signaling Technology (Danvers, MA.
1:1000 dilution). The loading control for Western blotting
was β-actin.

Flow cytometric analysis of the cell cycle
The cells were collected and washed twice with
phosphate-buffered saline followed by fixation in 70%
ethanol overnight. The cells were then centrifuged at
1500 g for 8 min, resuspended in 50μg/ml propidium
iodide (Sigma-Aldrich) in phosphate-buffered saline and
immediately analyzed in the FACStar flow cytometer
(Beckton-Dickinson, Mountain View, CA). Appropriate
settings of forward and side scatter gates were used to
examine 10 000 cells per experiment. Data were analysed
using ModFit software (Verity Software House, Topsham,
ME). Values were expressed as the mean and error
deviation of three independent experiments.

3′UTR luciferase reporter assays
The binding site of the miRNAs and 3′UTR of the
target genes were as predicted by TargetScan 5.0 and
Pictar. We synthesized single strands of 3′UTR of the
target genes that contained the binding site of the miRNAs.
Single strands of the 3′UTR of the target genes that deleted
five bases in the binding site of the miRNAs were then
synthesized as a mutant control. The oligonucleotides
used in these studies were as follows: 3′UTR of mutant
PTEN [which deleted eight bases (GGCAGTAT) in the
binding site of miR-200c]: AATTAAAACTTTATTTAT
G G C A G TAT T C ATA AT TA G C C T G A A AT G C A U .
www.impactjournals.com/oncotarget

Flow cytometric analysis of apoptosis
Cells were harvested, washed twice with PBS and
double stained with FITC-conjugated Annexin V and PI.
The cells were analysed by quadrant statistical analysis.
The Annexin V FITC was highlighted in green, and PI was
highlighted in red.
5215

Oncotarget

Wound-healing assay

were perfused and fixed with phosphate-buffered neutral
formalin before paraffin embedding; and 5-μm sections
were stained with hematoxylin and eosin. The metastases
were counted in a double-blind manner with the aid of a
dissecting microscope (Nikon, Tokyo, Japan).

To demonstrate the effect of miR-200c on the
migration and mobility of the 5-8F cells, Wound healing
assay was performed to evaluate 5-8F cell motility in
response to the depletion of miR 200c. At 48 h after
transfection with miRNA200c inhibitors, a total of 5×105
5-8F cells were plated into a6-wellplate and left overnight
to achieve sub-confluence. After scraping the cells with a
10μl pipette tip vertically to the marked lines and washing
with PBS three times to get rid of floating cells, a cell-free
space was created. Images were taken at 0 h and 24 h after
wounding under the inverted microscope.

Data analysis
Statistical analyses were carried out using the SPSS
version 15.0. The results are expressed as the mean±
S.E.M. Comparison of means between two groups was
performed using the two-tailed unpaired Student’s t-tests.
A two sided P-value of less than 0.05 was considered
statistically significant.

Transwell invasion assay
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